May 30,2007
Sen. Grassley seeks additional information about pricing and marketing of anti-anemia drugs
WASHINGTON --- Sen. Chuck Grassley is asking a leading drug maker to cooperate with his ongoing inquiry into the pricing and marketing of anti-anemia drugs given to kidney and cancer patients and the Food and Drug Administration’s access to data from the drug maker’s studies of such drugs.
The text of the letter Grassley sent today to Johnson & Johnson is below, along with the text of inquiries he made earlier this month and in April of the Food and Drug Administration, Amgen Inc. and the Centers for Medicare and Medicaid Services.
Grassley is Ranking Member of the Senate Committee on Finance.
###
Next Article Previous Article
Recent News
- Wyden, Sanders Demand Answers from Trump Administration Over Mass Layoffs that Threaten the Wellbeing of Children and Families
- Wyden, Sanders Demand Answers from Trump Administration Over Mass Layoffs that Threaten the Wellbeing of Children and Families
- Wyden, Cortez Masto Call for Criminal Investigation into Evidence of Fraud by Promoters Affiliated with IRS Nominee Billy Long
- Wyden Statement on Social Security Using Death Master List to Revoke Social Security Numbers
- Wyden, Whitehouse Lead Colleagues in Demanding Answers on DOGE’s Access to the Sensitive National Child Support Database